Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
Moderna(MRNA) stock is priced at $55.48, giving the company a market capitalization of 21.87B. It carries a P/E multiple of -6.91.
During the trading session on 2026-08-04, Moderna(MRNA) shares reached a daily high of $58.00 and a low of $52.66. At a current price of $55.48, the stock is +5.4% higher than the low and still -4.3% under the high.
Trading volume for Moderna(MRNA) stock has reached 5.18M, versus its average volume of 4.96M.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $85.60 and a low of $22.28.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $85.60 and a low of $22.28.
MRNA News
Citi raised the firm’s price target on Moderna (MRNA) to $60 from $41 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology spa...
In the past quarter, Moderna, Inc. reported second-quarter 2026 revenue of US$145 million versus US$142 million a year earlier, with a net loss of US$782 millio...
Moderna stock has delivered a strong 98.6% return over the past year, yet its broader valuation checks still lean expensive, so investors are weighing a sharp s...
Analyst ratings
65%
of 26 ratingsMore MRNA News
The COVID-19 vaccine maker reported sales of $145 million, better than the Wall Street estimate of $102.998 million. Lower COVID vaccine sales in the U.S. and...
Moderna’s (MRNA) latest earnings were better-than-expected. Jefferies (JEF) analyst Andrew Tsai explained that while quarterly earnings beat expectations, new d...
Moderna (MRNA) came out with a quarterly loss of $3.62 per share versus the Zacks Consensus Estimate of a loss of $3.84. This compares to earnings of $5.24 per...
Moderna narrowed its loss in the second quarter. Brian Snyder / Reuters Moderna MRNA 6.29 %increase; up pointing triangle narrowed its loss in the second quart...
(RTTNews) - Moderna, Inc (MRNA) released Loss for second quarter of -$782 million The company's earnings totaled -$782 million, or -$1.97 per share. This compa...
Moderna (MRNA) has been in focus after its recent quarter showed significant year over year revenue growth that beat market expectations, along with fresh Europ...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.